Breast Cancer

January 22, 2021

Findings of an epidemiological study show that regular aspirin use could boost survival in older patients with breast and bladder cancers, but more research is still needed.

January 06, 2021

Twice-weekly text message reminders did not improve adherence to aromatase inhibitors (AIs) for postmenopausal patients with early-stage breast cancer; therefore, increasing the odds of long-term adherence for this population will require more personalized approaches, explained Julie Gralow, MD.

January 06, 2021

The FDA has granted a fast track designation to the investigational antibody-drug conjugate (ADC) ARX788 for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer who have previously received 1 or more HER2-targeted regimens in the metastatic setting.

January 05, 2021

Patients with early-stage HER2-positive breast cancer should be treated with neoadjuvant therapy rather than surgery to determine how they will respond to ado-trastuzumab emtansine (T-DM1; Kadcyla)in the adjuvant setting, according to Ian E. Krop, MD, PhD, who added that although residual disease may serve as a potential predictive biomarker for response to this approach, the hunt for effective molecular biomarkers continues.

December 27, 2020

Several novel chemoimmunotherapy combinations have risen to the forefront of treatment in triple-negative breast cancer (TNBC), according to Neelima Vidula, MD. However, what the optimal chemotherapy backbone is, which PD-L1 assay should be utilized, and whether this approach will play a role in the neoadjuvant setting are all questions that remain unanswered.

December 17, 2020

The FDA has approved margetuximab-cmkb (Margenza) plus chemotherapy for use in adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which was for metastatic disease.

December 15, 2020

Gastrointestinal (GI) adverse events (AEs) that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide, according to research presented at the 2020 San Antonio Breast Cancer Symposium.

December 15, 2020

Four oncology nurse practitioners sat down and discussed the recent developments in the treatment of HER2-positive breast cancer and how to manage this group of patients during a worldwide pandemic.

December 14, 2020

When administering oral therapies for HER2+ breast cancer, discuss adverse events and medication adherence.

December 14, 2020

A poster presented at the 2020 San Antonio Breast Cancer Symposium found a trend towards less frequent care refusal when a safety net hospital introduced nurse breast navigators.